353 related articles for article (PubMed ID: 29460920)
1. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.
Chaparro M; Verreth A; Lobaton T; Gravito-Soares E; Julsgaard M; Savarino E; Magro F; Biron AI; Lopez-Serrano P; Casanova MJ; Gompertz M; Vitor S; Arroyo M; Pugliese D; Zabana Y; Vicente R; Aguas M; Shitrit BA; Gutierrez A; Doherty GA; Fernandez-Salazar L; Cadilla MJ; Huguet JM; OʼToole A; Stasi E; Marcos MN; Villoria A; Karmiris K; Rahier JF; Rodriguez C; Palomares DM; Fiorino G; Benitez JM; Principi M; Naftali T; Taxonera C; Mantzaris G; Sebkova L; Iade B; Lissner D; Bradley FI; Roman LA; Marin-Jimenez I; Merino O; Sierra M; Van Domselaar M; Caprioli F; Guerra I; Peixe P; Piqueras M; Rodriguez-Lago I; Ber Y; van Hoeve K; Torres P; Gravito-Soares M; Rudbeck-Resdal D; Bartolo O; Peixoto A; Martin G; Armuzzi A; Garre A; Donday MG; de Carpi MFJ; Gisbert JP
Am J Gastroenterol; 2018 Mar; 113(3):396-403. PubMed ID: 29460920
[TBL] [Abstract][Full Text] [Related]
2. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
[TBL] [Abstract][Full Text] [Related]
3. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation.
Duricova D; Dvorakova E; Hradsky O; Mitrova K; Durilova M; Kozeluhova J; Kohout P; Zarubova K; Bronsky J; Hradska N; Bronska E; Adamcova M; Machkova N; Hruba V; Bortlik M; Lukas M; Malickova K; Lukas M
Inflamm Bowel Dis; 2019 Mar; 25(4):789-796. PubMed ID: 30239799
[TBL] [Abstract][Full Text] [Related]
4. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Kanis SL; Modderman S; Escher JC; Erler N; Beukers R; de Boer N; Bodelier A; Depla ACTM; Dijkstra G; van Dijk ARM; Gilissen L; Hoentjen F; Jansen JM; Kuyvenhoven J; Mahmmod N; Mallant-Hent RC; van der Meulen-de Jong AE; Noruzi A; Oldenburg B; Oostenbrug LE; Ter Borg PCJ; Pierik M; Romberg-Camps M; Thijs W; West R; de Lima A; van der Woude CJ;
Gut; 2021 Jul; 70(7):1266-1274. PubMed ID: 33046558
[TBL] [Abstract][Full Text] [Related]
5. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.
Shihab Z; Yeomans ND; De Cruz P
J Crohns Colitis; 2016 Aug; 10(8):979-88. PubMed ID: 26755733
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants.
Kattah MG; Milush JM; Burt T; McCabe RP; Whang MI; Ma A; Mahadevan U
Clin Transl Gastroenterol; 2018 Apr; 9(4):143. PubMed ID: 29618720
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis.
Barenbrug L; Groen MT; Hoentjen F; van Drongelen J; Reek JMPAVD; Joosten I; de Jong EMGJ; van der Molen RG
J Autoimmun; 2021 Aug; 122():102676. PubMed ID: 34126302
[TBL] [Abstract][Full Text] [Related]
8. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
9. Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFα agents: a French nationwide population-based cohort.
Luu M; Benzenine E; Barkun A; Doret M; Michiels C; Degand T; Quantin C; Bardou M
Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1181-1188. PubMed ID: 31617226
[TBL] [Abstract][Full Text] [Related]
10. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
[TBL] [Abstract][Full Text] [Related]
12. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
[TBL] [Abstract][Full Text] [Related]
13. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease.
Kammerlander H; Nielsen J; Kjeldsen J; Knudsen T; Friedman S; Nørgård B
Inflamm Bowel Dis; 2017 Jun; 23(6):1011-1018. PubMed ID: 28346274
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero.
de Lima A; Kanis SL; Escher JC; van der Woude CJ
J Crohns Colitis; 2018 Jul; 12(8):948-953. PubMed ID: 29726943
[TBL] [Abstract][Full Text] [Related]
16. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
Roseira J; Ramos J
Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
Molander P; Färkkilä M; Kemppainen H; Blomster T; Jussila A; Mustonen H; Sipponen T
Scand J Gastroenterol; 2017 Mar; 52(3):284-290. PubMed ID: 27806638
[TBL] [Abstract][Full Text] [Related]
18. Adverse birth outcomes and early-life infections after in utero exposure to corticosteroids for inflammatory bowel disease: a Danish nationwide cohort study.
Jølving LR; Nielsen J; Andersen ML; Friedman S; Nørgård BM
BMC Med; 2023 Apr; 21(1):140. PubMed ID: 37046314
[TBL] [Abstract][Full Text] [Related]
19. Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study.
Wintzell V; Svanström H; Melbye M; Jess T; Olén O; Ludvigsson JF; Pasternak B
Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):845-853. PubMed ID: 31494100
[TBL] [Abstract][Full Text] [Related]
20. Maternal smoking during pregnancy and long-term neurological morbidity of the offspring.
Gutvirtz G; Wainstock T; Landau D; Sheiner E
Addict Behav; 2019 Jan; 88():86-91. PubMed ID: 30172166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
